References
- Likes K, Banner W, Chazez M. Centruroides exilicauda envenomation in Arizona. West J Med. 1984;141:634–637.
- Instituto Bioclon. Anascorp® (Centruroides (Scorpion) Immune F(ab′)2 (Equine)) Injection prescribing information. [cited 2017 May 30]. Available from: https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-bio-gen/documents/document/ucm266725.pdf
- Curry SC, Vance MV, Ryan PJ, et al. Envenomation by the scorpion Centruroides sculpturatus. Clin Toxicol. 1984;21:417–449.
- Mowry JB, Spyker DA, Cantilena LR Jr, et al. 2013 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 31st annual report. Clin Toxicol. 2014;52:1032–1283.
- Boyer LV, Theodorou AA, Berg RA, et al. Antivenom for critically ill children with neurotoxicity from scorpion stings. N Engl J Med. 2009;360:290–298.
- O’Connor A, Ruha AM. Clinical course of bark scorpion envenomation managed without antivenom. J Med Toxicol. 2012;8:258–262.
- Berg RA, Tarantino MD. Envenomation by the scorpion Centruroides exilicauda (C. sculpturatus): severe and unusual manifestations. Pediatrics. 1991;87:930–933.
- LoVecchio F, McBride C. Scorpion envenomations in young children in central Arizona. Clin Toxicol. 2003;41:937–940.
- Bond GR. Antivenin administration for Centruroides scorpion sting: risks and benefits. Ann Emerg Med. 1992;21:788–791.
- LoVecchio F, Welch S, Klemens J, et al. Incidence of immediate and delayed hypersensitivity to Centruroides antivenom. Ann Emerg Med. 1999;34:615–619.
- Armstrong EP, Bakall M, Skrepnek GH, et al. Is scorpion antivenom cost-effective as marketed in the United States? Toxicon. 2013;76:394–398.